Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The company’s shares opened today at $14.74.

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Elon Musk’s xAI has launched the Grok 3 series, boasting 10x more compute power than its predecessor. The lineup includes pre ...

Could Palantir Technologies stock (NASDAQ: PLTR) drop to $60 in the near future from its current price above $120? Does this ...

This is an executive interior configured for nine passengers. The cabin layout starts with a four club seat configuration, three place divan and dual aft berthable chairs all upholstered in gray ...

AppLovin has consistently exceeded expectations in recent quarters, largely due to the success of its AI-driven ad search ...